Latest Biotech News

Atrium Therapeutics emerged from Avidity Biosciences with a $270 million launch financing to pursue two RNA therapy programs targeting rare inherited cardiomyopathies. The spin‑out follows...

QL Biopharm closed a roughly $72 million (500 million CNY) Series C financing led by OrbiMed and Qiming Venture Partners to advance late‑stage programs in obesity. The capital infusion will...

Paul Chaplin, who led Bavarian Nordic for more than 30 years, announced his departure months after a proposed $3 billion takeover by private equity collapsed last November. The management change...

Novartis presented phase 2 data indicating its recently approved urticaria drug Rhapsido produced higher response rates in a food allergy cohort across three dose levels. The company framed the...

Wake Forest University researchers engineered CAR macrophages (CARMA) that demonstrated brain‑penetrant immunotherapy activity against lung‑cancer brain metastases in preclinical studies. The...

A University of Warwick study published in Nature Biomedical Engineering found that AI tools for cancer pathology are prone to “shortcut learning,” where models rely on spurious correlations in...

Manufacturers and regulators are pressing to eliminate open manipulations in cell therapy production to reduce contamination risk and scale operations. The article outlines how “open”...

IRB Barcelona has launched the country’s first end‑to‑end spatial‑omics workflow, uniting core facilities to support academic, clinical and industry users with tissue processing, multiplexed...

FDA Commissioner Marty Makary announced a pilot program that will pay quarterly bonuses to drug reviewers who complete reviews ahead of schedule, according to slides and a staff presentation...

Atrium Therapeutics launched with a $270 million financing to advance two RNA therapy candidates for rare inherited cardiac conditions, the company said. Atrium spun out of Avidity Biosciences...

The Phase 3 LITESPARK‑022 trial reported that combining belzutifan, a HIF‑2α inhibitor, with pembrolizumab significantly improved disease‑free survival in high‑risk clear‑cell renal cell carcinoma...

Novartis presented preliminary Phase 2 data evaluating Rhapsido, a drug recently approved for chronic spontaneous urticaria, in food allergy. The company reported that all three investigational...

Researchers discovered that unrelated bacteriophages disable the essential bacterial cell‑wall protein MurJ by locking it into a single conformation, halting peptidoglycan assembly and causing...

Researchers reported a platinum complex that is activated by X‑rays to enhance radiotherapy efficacy and amplify anti‑tumor immune responses in preclinical models. The compound operates via a...

Researchers unveiled a chemiluminescent microfluidic chip with dielectric wetting valves that non‑invasively measures embryo metabolites to predict implantation potential. The device integrates...

A newly reported wearable device combines ultrasound actuation with microneedle drug delivery to provide both immediate and sustained therapy for gouty arthritis. Published in npj Flexible...

Atrium Therapeutics launched with $270 million in initial financing to develop RNA therapies for rare inherited cardiac conditions. The company spun out from Avidity Biosciences after Avidity’s...

FDA Commissioner Marty Makary announced a pilot program to pay bonuses to drug reviewers who complete reviews ahead of schedule, with the first quarterly payments expected in August. The plan ties...

The phase 3 LITESPARK-022 trial reported that combining belzutifan, a HIF-2α inhibitor, with pembrolizumab significantly improved disease-free survival in high-risk clear cell renal cell carcinoma...

Novartis reported Phase 2 data indicating its recently approved hives drug, Rhapsido, produced higher response rates across three doses in a food allergy study. Company investigators presented...